ECRD 2026: Europe’s rare disease bottleneck is funding rather than science - Pharmaceutical Technology

Derisking assets to attract capital and rethinking funding models should be key priorities for Europe to retain its research pipeline. Derisking assets to attract capital and rethinking funding models should be key priorities for Europe to retain its research pipeline. Funding and regulatory complexity remain the core limitations to making rare disease therapies accessible to the patients who need them most. Image credit: [itakdalee]/Shutterstock.com Rare disease R&D investment is outpacing the broader biotech market, while the pipeline of innovative therapies continues to deepen. With enhanced sequencing and data infrastructure, Europe’s constraint is no longer scientific. Funding and regulatory complexity remain…

Source: Pharmaceutical Technology